АКИТА Джеффри И. (US),ЛОННИНГ Скот (US),ГРЕГОРИ Ричард К. Мл. (US),КУДЕЙ Амелия Б. (US)
申请号：
RU2013114365/15
公开号：
RU2013114365A
申请日:
2011.09.01
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of reducing the adverse effects of myocardial infarction in a patient, comprising administering a TGF-β antagonist to the patient during the acute stage of myocardial infarction. The method of claim 1, wherein the myocardial infarction is an acute myocardial infarction. The method of claim 1, wherein administration of the TGF-β antagonist is started within 120 hours after the onset of myocardial ischemia. The method of claim 1, wherein administration of the TGF-β antagonist is started within 72 hours after the onset of myocardial ischemia. The method of claim 1, wherein administration of the TGF-β antagonist is started within 48 hours after the onset of myocardial ischemia. The method of claim 1, wherein administration of the TGF-β antagonist is started within 24 hours after the onset of myocardial ischemia. The method of claim 1, wherein administration of the TGF-β antagonist is started within 12 hours after the onset of myocardial ischemia. The method according to claim 1, where the administration of a TGF-β antagonist is started before expressed infiltration by macrophages and mononuclear cells of the tissue affected by myocardial infarction. The method of claim 1, wherein administration of a TGF-β antagonist is started during a period characterized by neutrophilic tissue infiltration affected by myocardial infarction. The method of claim 1, wherein administration of a TGF-β antagonist is started during a period characterized by tissue necrosis affected by myocardial infarction. The method of claim 1, wherein the patient is a human or non-human mammal. The method of claim 1, wherein the method of reducing the adverse effects of myocardial infarction in a patient is a method of preserving myocardium. The method of claim 1, wherein the TGF-β antagonist can be selected from the group consisting of: (i) an antibody or antibody fragment that specifically binds to one or more isoforms of TGF-β； (ii) a TGF-β receptor or its soluble fragment； (iii) antibodies
